November 11, 2017

The MUST trial compared the effectiveness of systemic therapy vs. fluocinolone acetonide implant for severe uveitis. Intermediate, posterior and panuveitis patients were included. In a nonprespecified 7-year observational follow-up of 215 participants from the randomized clinical trial, patients who had systemic therapy had significantly better visual acuity compared with those who received the fluocinolone acetonide implant, by a mean of 7 letters. Previously, the trial had shown no difference at 2 years. Findings are limited by a 30% loss to follow up, with possible selection bias.